Camlipixant is a P2X3 antagonist. Studied patients had a baseline awake cough frequency of at least 25 coughs per hour. Researchers noted favorable changes in 24-hour and awake cough frequency ...

Both drugs are selective P2X3 receptor antagonists, designed to inhibit a hypersensitisation of the cough reflex in people struggling with chronic cough. At the moment there are no approved ...

MSD – known as Merck & Co in North America – had submitted the oral selective P2X3 receptor antagonist to the US regulator as a treatment for refractory chronic cough (RCC) or unexplained ...

AF-219 works by selectively blocking the P2X3 receptors stopping the mechanism by which certain airway nerves become hyper-sensitized. The drug has already been shown to be effective in reducing cough ...